Efficacy of pasireotide LAR for acromegaly: a prolonged real-world monocentric study

Efficacy of pasireotide LAR for acromegaly: a prolonged real-world monocentric study

BackgroundAcromegaly is caused by excessive growth hormone (GH) and insulin-like growth factor 1 (IGF1). Medical therapy plays a role as a treatment option for persistent disease after non-curative surgery or as a first-line therapy when surgery is not feasible. Pasireotide-LAR (Pas-LAR) is recommen...

Full description

Bibliographic Details
Main Authors: Vittoria Favero, Benedetta Zampetti, Emanuela I. Carioni, Paolo Dalino Ciaramella, Erika Grossrubatscher, Daniela Dallabonzana, Iacopo Chiodini, Renato Cozzi
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-02-01
Series:Frontiers in Endocrinology
Subjects:
acromegaly
pasireotide
somatostatin receptor subtype 5 (SSTR5)
insulin-like growth factor 1
growth hormone
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2024.1344728/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2024.1344728/full

Similar Items